Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Ann Allergy Asthma Immunol ; 124(5): 494-499, 2020 05.
Article in English | MEDLINE | ID: mdl-31923549

ABSTRACT

BACKGROUND: Extending the drug provocation test (DPT) period is recommended for patients with suspected nonimmediate beta-lactam antibiotic (BLA) allergy and negative DPT. No consensus has been reached regarding the duration of prolonged provocation. OBJECTIVE: We aimed to determine the negative predictive value (NPV) of the 5-day extended DPT. METHODS: Parents of patients with suspected nonimmediate mild cutaneous reactions with BLAs who had been subjected to 5-day DPT with culprit drugs were questioned by telephone interview about reexposure to the tested drug. Patients with reported reaction during reexposure were reevaluated. Skin tests and serum-specific immunoglobulin E (IgE) analysis were not performed before first DPT. RESULTS: A total of 355 patients had negative results in 5-day DPT. The median age at DPT was 4.2 years, and 52.9% were male. The families of 255 patients (72%) could be contacted. Of these 255 patients, 179 (70%) had used the same drug, and reactions were reported for 6 (3.4%) of those patients, who were subsequently reevaluated. Five of the 6 patients had DPT with amoxicillin-clavulanate and 1 with cefixime. When detailed history was taken, 2 of the 5 patients with amoxicillin-clavulanate reaction were found to have used the drug unintentionally after their reaction to reexposure and did not have any symptoms. One of the patients underwent allergy workup and tested negative, and the other 2 refused the test. The patient with reported cefixime reaction underwent repeated allergy workup and tested negative. Therefore, the NPV of 5-day prolonged DPT was 98.9%. CONCLUSION: The 5-day prolonged DPT has high NPV and seems appropriate in duration for children with suspected nonimmediate-BLA allergy.


Subject(s)
Amoxicillin-Potassium Clavulanate Combination/therapeutic use , Anti-Bacterial Agents/therapeutic use , Cefixime/therapeutic use , Drug Hypersensitivity/diagnosis , Immunization/methods , Time Factors , beta-Lactams/therapeutic use , Administration, Oral , Allergens/immunology , Amoxicillin-Potassium Clavulanate Combination/adverse effects , Amoxicillin-Potassium Clavulanate Combination/immunology , Anti-Bacterial Agents/adverse effects , Anti-Bacterial Agents/immunology , Cefixime/adverse effects , Child , Child, Preschool , Female , Humans , Hypersensitivity, Delayed , Immunoglobulin E/metabolism , Infant , Male , Predictive Value of Tests , beta-Lactams/adverse effects , beta-Lactams/immunology
2.
J Infect Dev Ctries ; 16(4): 712-716, 2022 04 30.
Article in English | MEDLINE | ID: mdl-35544635

ABSTRACT

The hepatosplenic (HS) form of cat scratch disease (CSD) is rarely seen; however, management of the treatment is challenging for clinicians. Monotherapy or combination regimens may be preferred based on severity of cases. Along with that, there are uncertainties as to the combination and duration of antibiotics effective against the microorganisms. In this report, a 12-year-old girl diagnosed with HS-CSD and unresponsive to primary treatment with macrolide group antibiotic was presented. The patient had liver findings compatible with CSD, confirmed radiologically and pathologically, and Bartonella henselae indirect immunofluorescence assay IgG was positive at 1/2048 titre. A combination therapy for six months with doxycycline and rifampicin was initiated, and the patient was successfully treated. The preference for monotherapy or combination regimen in HS-CSD is predominantly determined by the clinician according to the severity of the patient's clinical findings. The effectivity of antimicrobial regimen in HS-CSD requires further investigation.


Subject(s)
Bartonella henselae , Cat-Scratch Disease , Anti-Bacterial Agents/therapeutic use , Antibodies, Bacterial , Cat-Scratch Disease/diagnosis , Cat-Scratch Disease/drug therapy , Child , Fluorescent Antibody Technique, Indirect , Humans , Immunoglobulin G
SELECTION OF CITATIONS
SEARCH DETAIL